CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL) in China
Two NMPA-approved CD19 CAR-T products treat relapsed or refractory B-ALL in China — one for adults, and one specifically studied in children and young adults aged 3–21.
Who this is for
B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive blood cancer that progresses quickly, which is why eligibility review and manufacturing speed both matter more here than in slower-moving cancers. CAR-T is generally considered for patients whose leukemia has relapsed or not responded to standard induction chemotherapy.
| Product | Manufacturer | Approved for |
|---|---|---|
| Yuanruida (inaticabtagene autoleucel) | Juventas Cell Therapy | Adults with relapsed/refractory B-cell ALL |
| Pulidekai (pujiaolunsai injection) | Chongqing Precision Biotech | CD19-positive relapsed/refractory B-ALL, ages 3–21. Patients relapsing more than 12 months after first remission must have received salvage chemotherapy first. |
Why speed matters more for leukemia
Unlike slower-growing lymphomas, B-ALL can progress within weeks. Our role is to compress every non-clinical delay — visa processing, records transfer, hospital scheduling — so that the clinical timeline (apheresis, manufacturing, infusion) is the only thing determining when treatment happens. We prioritize same-week record review for suspected B-ALL referrals.
Family and pediatric considerations
For patients aged 3–21, a parent or guardian travels and stays throughout treatment. We arrange extended-stay accommodation suitable for families, pediatric-experienced interpreters, and coordination with child-life support where the treating hospital offers it.
Next step
Send the most recent bone marrow biopsy, flow cytometry / minimal residual disease (MRD) results and treatment history for a free, prioritized eligibility review. Start your case review →